OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
STRR
Star Equity Holdings, Inc.
There isn't enough reported data to score STRR yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STRR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
STRR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STRR PE Valuation
STRR has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STRR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for STRR, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STRR on earnings quality, reporting a profit while its opponent remains loss making.
STRR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.50 | — |
| Q3 2026 | -$2.43 | -$0.86 |
| Q2 2026 | -$2.54 | -$1.23 |
| Q1 2026 | -$2.27 | -$1.04 |
| Q4 2025 | -$1.85 | -$0.26 |
| Q3 2025 | -$1.57 | -$0.43 |
| Q2 2025 | -$1.31 | -$0.62 |
| Q1 2025 | -$1.23 | -$0.87 |
| Q4 2024 | -$1.59 | -327% |
STRR lost $2.43 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STRR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over STRR on profitability, with a higher operating margin.
STRR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.9M | +12% |
| Q2 2026 | $54.9M | +55% |
| Q1 2026 | $50.1M | +57% |
| Q4 2025 | $56.8M | +69% |
| Q3 2025 | $48M | +30% |
| Q2 2025 | $35.5M | -0.5% |
| Q1 2025 | $31.9M | -6% |
| Q4 2024 | $33.6M | -1.1% |
STRR's revenue has grown year over year for five quarters in a row: $54M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.4% | +0.1 points |
| Q2 2026 | -2.5% | -1.9 points |
| Q1 2026 | -8% | -2.6 points |
| Q4 2025 | -0.2% | +0.2 points |
| Q3 2025 | -3.4% | -2.2 points |
| Q2 2025 | -0.6% | -0.1 points |
| Q1 2025 | -5.4% | +3.6 points |
| Q4 2024 | -0.4% | +3.4 points |
STRR's operating margin was −3.4% last quarter, about level with the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over STRR on cash generation, producing positive trailing cash flow while its opponent burns cash.
STRR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60K | +$3.4M |
| Q2 2026 | -$3.2M | -3269% |
| Q1 2026 | -$2.7M | -$1.9M |
| Q4 2025 | -$4.9M | -342% |
| Q3 2025 | -$3.4M | -368% |
| Q2 2025 | $102K | +$4.4M |
| Q1 2025 | -$808K | +$986K |
| Q4 2024 | $2M | -39% |
STRR's free cash flow was −$11M over the past year, against −$2M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STRR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -3K shares |
| 1 year | +13% | +438K shares |
| 3 years | +18% | +560K shares |
| 5 years | +22% | +679K shares |
| Available history | +18% | +570K shares |
STRR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $306,000 |
| Q2 2026 | $157,000 |
| Q1 2026 | $712,000 |
| Q4 2025 | $66,000 |
| Q3 2025 | $2.6M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
STRR spent $1M buying back its own shares over the past year, down 52% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STRR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -7.9x | Net Cash |
| Q3 2023 | -4.6x | Net Cash |
| Q2 2023 | -4.9x | Net Cash |
| Q1 2023 | -2.9x | Net Cash |
| Q4 2022 | -2.4x | Net Cash |
| Q3 2022 | -1.7x | Net Cash |
| Q2 2022 | -1.9x | Net Cash |
| Q1 2022 | -2.0x | Net Cash |
STRR has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STRR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.3 | Neutral |
| Stochastic | 26.2 | Neutral |
STRR's weekly RSI is 48 (neutral) and its Stochastic is 26 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STRR PE vs Healthcare Sector
| Metric | STRR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STRR has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STRR on trend strength, trading above more of its moving averages.
STRR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.84 | 1.6% above |
| 20 week MA | $10.3 | 2.9% below |
| 50 week MA | $10.3 | 3.1% below |
| 100 week MA | $10.4 | 3.6% below |
| 200 week MA | $14.2 | 30% below |
STRR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 30% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STRR on returns for 2026, with the stronger performance.
STRR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.5 | $10.7 | -14% |
| 2021 | $10.7 | $27.4 | +155% |
| 2022 | $27.4 | $23.5 | -14% |
| 2023 | $23.5 | $15.5 | -34% |
| 2024 | $15.5 | $13.4 | -14% |
| 2025 | $13.4 | $10.9 | -18% |
| 2026 YTD | $10.9 | $10.0 | -8.4% |
STRR has finished four years in a row lower, and it's down 8.4% so far in 2026.